跳至主要内容
临床试验/NCT05831917
NCT05831917招募中不适用

MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer

Sichuan Cancer Hospital and Research Institute1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2023年1月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
41
试验地点
1
主要终点
Swallowing Difficulty

研究概览

简要总结

Recently developed hybrid machines (MRidian®-CE approval since 2016), consisting of a linear accelerator and an integrated low-field MRI, could allow better visualization of tumor and organs at risk during patient positioning and daily treatment finally repetitive adaptation of target volumes according to changes in patient weight and tumor anatomy during the radiotherapy course. These procedures would facilitate a high-precision treatment and help reduce dose exposure of critical structures.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18-70 years old;
  • •I-IVb stage oral cancer, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer confirmed by histopathology or cytology (AJCC 8th edition);
  • •Receiving radical synchronous radiotherapy and chemotherapy;
  • •According to the RECIST version 1.1 evaluation criteria, at least one measurable lesion is present;
  • •ECOG PS score 0-1;
  • •Hematology indicators are basically normal: white blood cell count ≥ 4 × 109/L; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin ≥ 90g/L; Kidney function is basically normal: serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl)>60 mL/min (using Cockcroft Fault formula): Female CrCl=(140 age) × Body weight (kg) × 0.85 / (72 × Scr mg/dl); Male CrCl=(140 age) × Body weight (kg) × 1.00 / (72 × Scr mg/dl) Liver function is basically normal: serum total bilirubin ≤ 1.5 × ULN; Cereal grass transaminase (AST) ≤ 2.5 × ULN; Glutamate transaminase (ALT) ≤ 2.5 × ULN;
  • •Having sufficient cognitive ability to complete the questionnaire survey;
  • •Able to understand and willing to sign a written informed consent form.

排除标准

  • •There is evidence of swallowing dysfunction (unrelated to HNSCC);
  • •Patients who have previously received radiotherapy for the head and neck region;
  • •Recurrent or metastatic patients;
  • •Involvement of posterior pharyngeal wall, posterior ring, and posterior pharyngeal lymph nodes;
  • •Previous tumor resection surgery or major head and neck surgery (excluding biopsy/tonsillectomy);
  • •Previous tracheotomy;
  • •Participated in other interventional clinical trials within 30 days prior to screening;
  • •Individuals with a history of other malignant tumors (excluding cured skin basal cell carcinoma)
  • •There are concurrent diseases with poor control (such as heart failure, severe lung disease, severe liver disease, mental illness, etc.);
  • •Individuals who are allergic to the use of drugs or their components in this protocol;
  • •Pregnant (confirmed by blood or urine HCG testing) or lactating women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment;
  • •Researchers believe that it is not suitable to participate in this study;
  • •Those who are unwilling to participate in this study or unable to sign an informed consent form;

研究组 & 干预措施

Treatment Group

Experimental

干预措施: Radiotherapy (Radiation)

结局指标

主要结局

Swallowing Difficulty

时间窗: 12 months

Swallowing Difficulty will be assessed by MDADI swallowing difficulty score

次要结局

未报告次要终点

研究者

发起方
Sichuan Cancer Hospital and Research Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yangkun Luo

Study Director

Sichuan Cancer Hospital and Research Institute

研究点 (1)

Loading locations...

相似试验